MapLight Therapeutics director Troy Cox buys $148,702 in shares By Investing.com

Troy Cox, a director at MapLight Therapeutics, Inc. (), recently acquired 15,620 shares of the company’s common stock for a total value of $148,702. The transaction took place on July 28, 2026.

The shares were purchased at a weighted average price of $9.52 per share, with individual transaction prices ranging from $9.305 to $9.78. The stock has since risen to $12.31, representing a gain of nearly 30% from the director’s purchase price, though the shares remain down 65% over the past week amid high volatility. Following this acquisition, Mr. Cox indirectly holds 15,620 shares through the Troy M Cox & Adeo C Alday JT Revocable Trust dtd 5/28/25, where he serves as co-trustee with his spouse and has voting and dispositive power.

In other recent news, MapLight Therapeutics has faced several adjustments to its stock price targets following the results of its Phase 2 ZEPHYR trial. BMO Capital reduced its price target on the company to $20 from $46, citing the trial data as a setback for the company’s schizophrenia treatment opportunity. Canaccord also lowered its target to $24 from $43 but maintained a Buy rating, noting that the trial met its primary and key secondary endpoints. Similarly, H.C. Wainwright decreased its target to $26 from $45 while keeping a Buy rating, emphasizing the trial’s achievement of a statistically significant reduction in symptoms. Morgan Stanley downgraded MapLight Therapeutics to Equalweight from Overweight, adjusting its price target to $21 from $34 due to the trial’s pharmacological activity results. Wolfe Research also cut its price target to $30 from $60, maintaining an Outperform rating despite the trial data falling below investor expectations. These developments highlight the varied analyst responses to the trial outcomes, which have significantly influenced their forecasts and ratings.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.